文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19患者体外膜氧合支持后的院内与6个月结局(EuroECMO-COVID):多中心前瞻性观察研究

In-hospital and 6-month outcomes in patients with COVID-19 supported with extracorporeal membrane oxygenation (EuroECMO-COVID): a multicentre, prospective observational study.
PubMed 文献 · Lancet Respir Med · 2022-11-16
一句话结论COVID-19 ECMO患者院内死亡率50%,6个月存活者达95%,年龄≥60岁、ECMO前用正性肌力药/升压药、插管至ECMO≥4天与院内死亡相关。

EuroECMO-COVID为欧洲体外生命支持组织发起的多中心前瞻性观察研究,纳入2020年3月1日至9月13日第一波疫情期间21国133中心≥16岁因难治性COVID-19接受ECMO支持的1215例患者(男942例、女267例,中位年龄53岁)。主要终点院内死亡率为50%(602/1215),6个月时577例有数据者中547例(95%)存活。混合Cox分析显示年龄≥60岁、ECMO前使用正性肌力药和升压药、慢性肾衰竭、插管至ECMO启动≥4天与院内死亡风险升高相关。6个月时24%(102/431)恢复全职工作,17%(88/522)需呼吸康复,常见残留症状为呼吸困难35%(185/523)。作者认为年龄、插管至ECMO时机及ECMO前正性肌力药/升压药使用是分析结局的重要因素,长期症状提示需专门ECMO后随访项目。

要点

  • 1215例COVID-19 ECMO患者院内死亡率为50%(602/1215),至少发生一种并发症者占74%(852/1215)。
  • 6个月随访时有数据者中95%(547/577)存活,24%(102/431)恢复全职工作、13%(57/428)恢复兼职工作。
  • 混合Cox分析:年龄≥60岁、ECMO前使用正性肌力药和升压药、慢性肾衰竭、插管至ECMO启动≥4天与院内死亡风险升高相关。
  • 多器官衰竭是主要死因,占528例有数据死亡患者中的36%(192/528)。
  • 6个月时17%(88/522)需呼吸康复,最常见残留症状为呼吸困难35%(185/523),心脏症状10%(52/514),神经认知症状13%(66/512)。

适用人群与场景

  • 2020年3月1日至9月13日第一波疫情期间,21国133中心≥16岁因难治性COVID-19接受ECMO支持的患者。
  • 研究为前瞻性、多中心、观察性研究,由欧洲体外生命支持组织发起。

研究设计与关键结果

  • 研究类型:多中心前瞻性观察研究(EuroECMO-COVID,NCT04366921),纳入1215例患者,男942例(78%)、女267例(22%),中位年龄53岁(IQR 46-60),中位ECMO时长15天(IQR 8-27)。
  • 主要终点:院内死亡602/1215(50%);6个月时577例有数据者中547例(95%)存活。
  • 混合Cox分析:年龄≥60岁、ECMO前使用正性肌力药和升压药、慢性肾衰竭、插管至ECMO启动≥4天与院内死亡风险升高相关。
  • 并发症:852/1215(74%)患者至少发生一种并发症;多器官衰竭占528例有数据死亡患者的36%(192/528),为主要死因。
  • 6个月功能状态:431例有数据者中102例(24%)恢复全职工作,428例有数据者中57例(13%)恢复兼职工作。
  • 6个月残留症状:522例有数据者中88例(17%)需呼吸康复;523例中185例(35%)有呼吸困难,514例中52例(10%)有心脏症状,512例中66例(13%)有神经认知症状。

证据类型、等级与局限

  • 证据类型:多中心前瞻性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,患者年龄、插管至ECMO时机(<4天 vs ≥4天)及正性肌力药和升压药使用是分析COVID-19 ECMO患者结局时必须考虑的重要因素。
  • 作者认为,尽管出院后存活情况良好,但持续存在的长期症状提示需要专门的ECMO后随访项目。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Extracorporeal membrane oxygenation (ECMO) has been widely used in patients with COVID-19, but uncertainty remains about the determinants of in-hospital mortality and data on post-discharge outcomes are scarce. The aims of this study were to investigate the variables associated with in-hospital outcomes in patients who received ECMO during the first wave of COVID-19 and to describe the status of patients 6 months after ECMO initiation.

METHODS: EuroECMO-COVID is a prospective, multicentre, observational study developed by the European Extracorporeal Life Support Organization. This study was based on data from patients aged 16 years or older who received ECMO support for refractory COVID-19 during the first wave of the pandemic-from March 1 to Sept 13, 2020-at 133 centres in 21 countries. In-hospital mortality and mortality 6 months after ECMO initiation were the primary outcomes. Mixed-Cox proportional hazards models were used to investigate associations between patient and management-related variables (eg, patient demographics, comorbidities, pre-ECMO status, and ECMO characteristics and complications) and in-hospital deaths. Survival status at 6 months was established through patient contact or institutional charts review. This study is registered with ClinicalTrials.gov, NCT04366921, and is ongoing.

FINDINGS: Between March 1 and Sept 13, 2020, 1215 patients (942 [78%] men and 267 [22%] women; median age 53 years [IQR 46-60]) were included in the study. Median ECMO duration was 15 days (IQR 8-27). 602 (50%) of 1215 patients died in hospital, and 852 (74%) patients had at least one complication. Multiorgan failure was the leading cause of death (192 [36%] of 528 patients who died with available data). In mixed-Cox analyses, age of 60 years or older, use of inotropes and vasopressors before ECMO initiation, chronic renal failure, and time from intubation to ECMO initiation of 4 days or more were associated with higher in-hospital mortality. 613 patients did not die in hospital, and 547 (95%) of 577 patients for whom data were available were alive at 6 months. 102 (24%) of 431 patients had returned to full-time work at 6 months, and 57 (13%) of 428 patients had returned to part-time work. At 6 months, respiratory rehabilitation was required in 88 (17%) of 522 patients with available data, and the most common residual symptoms included dyspnoea (185 [35%] of 523 patients) and cardiac (52 [10%] of 514 patients) or neurocognitive (66 [13%] of 512 patients) symptoms.

INTERPRETATION: Patient's age, timing of cannulation (<4 days vs ≥4 days from intubation), and use of inotropes and vasopressors are essential factors to consider when analysing the outcomes of patients receiving ECMO for COVID-19. Despite post-discharge survival being favourable, persisting long-term symptoms suggest that dedicated post-ECMO follow-up programmes are required.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Lorusso R, De Piero ME, Mariani S, et al. In-hospital and 6-month outcomes in patients with COVID-19 supported with extracorporeal membrane oxygenation (EuroECMO-COVID): a multicentre, prospective observational study. Lancet Respir Med. 2022. PMID: 36402148. doi:10.1016/S2213-2600(22)00403-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。